CYBERDYNE

Consolidated Financial Result Briefing for the fiscal year ended March 31, 2026

CYBERDYNE, Inc. (Ticker Code: 7779)
May 14, 2026

Consolidated financial statements

FY2025 Consolidated results summary (IFRS)

Consolidated revenue decreased due to the impact of the sale of subsidiaries in the previous fiscal year, while operating profit improved year on year.
Profit before tax and profit attributable to owners of parent improved year on year, mainly due to gains on valuation of investment securities and other factors.

(Millions of yen)	FY2024	FY2025	+/-	+/- %
Revenue	4,384	3,846	△ 538	△ 12.3%
Operating profit (loss)	△ 926	△ 601	+ 325	-
Profit (loss) before tax	△ 879	589	+ 1,469	-
Profit (loss) attributable to owners of parent	△ 577	153	+ 730	-

Revenue

3,846 Million
YoY -538 Million (-12.3%)

- EMEA product rentals: -27 million yen (business -48 million yen, forex +21 million yen)
- Domestic & APAC product rentals, etc.: +5 million yen (business +16 million yen, forex –11 million yen)
- Treatment services: –74 million yen (business –55 million yen, forex –19 million yen)
- Others: LeyLine –406 million yen, domestic –36 million yen

Operating profit (loss)

-601 Million
YoY +325 Million

- EMEA product rentals: -32 million yen (business -41 million yen, forex +9 million yen)
- Domestic & APAC product rentals, etc.: +21 million yen (business +29 million yen, forex –8 million yen)
- Treatment services: +72 million yen (business +72 million yen, forex 0 million yen)
- Others: LeyLine +214 million yen, domestic +37 million yen
- R&D and head office expenses, etc.: +50 million yen

Profit (loss) before tax

589 Million
YoY +1,469 Million

- Operating profit variance: +325 million yen
- CEJ fund gains/losses +456 (FY2025 284, FY2024 -172)
- Difference in Financial income/expenses +680 (FY2025 916, FY2024 236)
  Including Provision for doubtful accounts for LeyLine -252 million yen in FY2025
- Equity in earnings of affiliates +8

※ Exchange Rate USD/JPY: Mar 2025 149.52 → Sep 2025 148.88 → Mar 2026 159.88 (YoY: Mar 2024 151.41 → Sep 2024 142.73 → Mar 2025 149.52)
EUR/JPY: Mar 2025 162.08 → Sep 2025 174.47 → Mar 2026 183.41 (YoY: Mar 2024 163.24 → Sep 2024 159.43 → Mar 2025 162.08)

Consolidated results: Revenue / Operating profit (Margin)

Product rentals and related services recorded year-on-year increased in Japan, with higher revenue and profit, while overseas operations recorded lower revenue and profit, partly due to the impact of the lump-sum sale to Ukraine at the end of the previous fiscal year.

Treatment services recorded achieved higher profit despite lower revenue.

(Millions of yen)		FY2024	FY2025	+/-	+/- %
Product rental	Revenue Operating Profit (Margin %)	2,024 939 (46%)	2,003 892 (45%)	△ 22 △ 47 (△2%)	△1% △5%
Treatment service	Revenue Operating Profit (Margin %)	1,711 △ 219 (△13%)	1,636 △ 147 (△9%)	△ 74 + 72 (+4%)	△4% -
Others	Revenue Operating Profit (Margin %)	649 △ 249 (△38%)	207 1 (1%)	△ 442 + 250 (+39%)	△68% -
R&D expenses& Head office expenses	Adjusted amount	△ 1,396	△ 1,347	+ 50	-
Consolidated total(IFRS)	Revenue Operating Profit (Margin %)	4,384 △ 926 (△21%)	3,846 △ 601 (△16%)	△ 538 + 325 (+5%)	△12% -

- Amount of operating profit or loss, which is revenue minus operating expenses, for each business
- Adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

- Product rental：Revenue from rental of the Group's products（includes revenue from sales）
- Treatment service：Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
- Others：Revenue from the Group's other business (e.g. subsidiary in Sleeping App)

Revenue by geographical regions and type of transaction

(Unit : Millions of yen) Top : FY2025 (Bottom : FY2024)	Japan	EMEA	APAC	AMER	Total	YoY
Product rental	974 (947)	451 (477)	540 (562)	38 (39)	2,003 (2,024)	△ 22 (△ 1%)
Treatment Service	120 (129)	71 (56)	- (-)	1,445 (1,526)	1,636 (1,711)	△ 74 (△ 4%)
Others	207 (243)	- (406) *	- (-)	- (-)	207 (649)	△ 442 (△ 68%)
Total	1,302 (1,319)	522 (939)	540 (562)	1,483 (1,565)	3,846 (4,384)	△ 538 (△ 12%)
YoY	△ 17 (△ 1%)	△ 417 (△ 44%)	△ 22 (△ 4%)	△ 82 (△ 5%)		
	Domestic	Foreign				
Revenue to sales ratio	34%	66%			100%	

EMEA :Europe, the Middle East and Africa
APAC : Asia-Pacific *Excluding Japan
AMER : North, Central and South America

* Impact of the sale of LeyLine GmbH (at the end of February 2025)

Rental revenue by each products

Domestic sales increased mainly driven by the HAL Lower Limb Type (including the small-size model) and the HAL Single Joint Type.
Overseas, although sales were unable to offset the lump-sum shipment to Ukraine made at the end of the previous fiscal year, sales of the Medical HAL Lower Limb Type increased mainly in Germany.

(Unit : Millions of yen) Top : FY2025 (Bottom : FY2024)	Type of product	In Japan	Outside Japan	Total
Cybernics Treatment Functional improvement and regeneration	Medical HAL Lower Limb Type	432 (372)	691 (617)	1,122 (990)
	Non-medical HAL Lower Limb Type	147 (165)	- (-)	147 (165)
	HAL Single Joint Type	95 (88)	156 (155)	251 (243)
Well-being and care	HAL Lumbar Type	94 (105)	144 (213)	237 (318)
Labor Support	HAL Lumbar Type	37 (38)	- (-)	37 (38)
	Mobile robot (CL02 etc.)	80 (75)	- (-)	80 (75)
Other（Acoustic X、Other products）		90 (103)	38 (93)	128 (196)
Total		974 (947)	1,028 (1,078)	2,003 (2,024)

Business Policy and Initiatives for Business Growth

Realization of “Techno-peer Support Society”

A future society where people and technology coexists, cooperates and mutually support each other

For wide variety of people faced with health, physical function, cognitive and psychological problems
A safe and secure society (well-being society) where people of all generations can increase their independence, freedom and solve various problems in their lives



→ Create “Cybernics Industry”, a new industry that follows Robot and IT Industry

Cybernics Technology: Innovative core technology of Cybernics Industry

Cybernics: Fuses and combines humans, AI-Robots and Information Systems

***Cybernics:** Science and technology in cutting-edge areas that combine different fields such as brain/neuroscience, physiology, artificial intelligence (AI), robotics, information technology (IT), psychology, economy and innovation with a focus on Human, AI-robots and Information Systems to realize the fusion of bio/medical technologies and AI, robotics and information technologies.

(Reference)
The Cabinet Office's FIRST, ImPACT, and SIP programs address Cybernics as pioneering cutting-edge innovative science and technology areas

→ Toward the creation of the "Cybnics Industry" following the robotics and IT industries

Business development centered on Cybernics (HCPS-integrated Cybernics with Physical AI) within a fusion space of humans and cyber/physical space

CYBERDYNE

Improving the well-being of seniors and people with disability

Improving the well-being through supporting and supervising solutions



Towards the 5th Industrial Revolutions!
"Human"+"Cyber/Physical Space"

HCPS-integrated Cybernics with Physical AI Cybernics Industry

that will follow Robot and IT Industry



Prevention, early detection and medical/healthcare



Work support and improving efficiency through AI automation



Future of medical healthcare and healthy life
Prevention/early detection, medicine, rehabilitation/long-term care

Medical/Healthcare/Healthy life

Pre-Hospital
Early medical・life period Prevent/early detection

Hospital
Diagnose, treat, inpatient/outpatient

Post-Hospital
Late medical・life period : rehab/long-term care

early medical・life period

Acute

Recovery

Late medical・life period

Household・work place・life space

Household・work place・life space



Close coordination, fusion between medical and non-medical field to evolve into comprehensive initiatives

Wearable cyborg HAL

HAL identified as the only device that induces neuroplasticity and provides comprehensive therapeutic effects — published in an international medical journal (comparison with passively controlled exoskeleton-type devices)



Review Article

AO SPINE

Actively Controlled Exoskeletons Show Improved Function and Neuroplasticity Compared to Passive Control: A Systematic Review

Global Spine Journal
2025, Vol. 15(8) 3933–3952

DOI: 10.1177/21925682251343529
journals.sagepub.com/home/gsj
Sage

Ka Ioi Argu
James Gedd
and Darren

A systematic review analyzed 27 clinical studies selected from 555 publications released over a 12-year period, providing one of the highest levels of scientific evidence.

Abstract

Study Design: Systematic Review.

Objectives: To determine whether actively controlled exoskeletons or passively controlled exoskeletons are better at rehabilitating patients with SCIs.

Methods: A literature search between January 2011 to June 2023 on Pubmed Central, Pubmed, Web of Science and Embase was carried out. Exoskeletons were classified as actively controlled if they detect bioelectrical signals (HAL). All other exoskeletons were classified as passively controlled (ReWalk, Ekso, H-MEX, Atlante, Indego, Rex Bionics, SuitX Phoenix, Lokomat and HANK). Functional outcomes used were 6 minute walk test (6MWT) distance and 10 metre walk test (10MWT) speed. Further subgroup analysis was carried out for acute and chronic SCI patients. All outcomes were examined without the aid of the exoskeleton device. Secondary outcomes including continence, pain and quality of life were also examined.

Results: 555 articles were identified in the initial search and 27 were included in the review resulting in a total of 591 patients and 10 different exoskeleton models. HAL was the only exoskeleton to show improvements in both mobility and all secondary health outcomes. HANK and Ekso also showed improvements in mobility. Rewalk showed improvements in all secondary health outcomes with Ekso only showing improvements in QoL. No other exoskeletons showed significant improvements.

Conclusion: In conclusion, the actively controlled exoskeleton HAL showed improvement in all outcomes of interest suggesting that neuroplasticity could be induced with HAL rehabilitation allowing the weakened bioelectrical signals to transcend the SCI to show genuine improvements.

In this review, HAL was compared with nine other passively controlled exoskeleton-type devices (devices that repeatedly perform movements through robotic control). The results clearly demonstrated that only HAL induces neuroplasticity and provides comprehensive therapeutic effects across multiple health outcomes associated with spinal cord injury (SCI).

The paper discusses that the repetitive neuromuscular process established between the central and peripheral nervous systems—made possible by HAL's core principles—facilitates the learning and reinforcement of neural signaling in the brain and spinal cord. This process ultimately leads to the reconstruction and reactivation of spinal circuits below the site of spinal cord injury and the partial reinnervation of neural pathways.

Through this mechanism of inducing neuroplasticity, HAL demonstrated consistent improvements not only in primary mobility functions such as walking ability but also in secondary health indicators, including urinary and bowel function (continence), pain reduction, and overall quality of life (QoL).

Wearable cyborg HAL

HAL Elicits Neuroplasticity in the Brain

Cerebral evidence supports that HAL directly engages the user's central nervous system

Cerebral Correlates of Robot-Assisted Upper Limb Motion Driven by Motor Intention in Healthy Individuals: An fNIRS Study

Margaux Noémie Lafitte, Christina Sylvia Andrea, Hideki Kadone, Eiichi Hoshino, Masashi Yamazaki, Yasuyo Minagawa, and Kenji Suzuki, *Senior Member, IEEE*

***Abstract*— The past few years have seen an exponential growth of the robot-assisted rehabilitation field and new technological developments allowing the integration of the user's intention through detection of physiological information. The inclusion of motor intention is thought to be promising for motor rehabilitation and to facilitate neuroplasticity potentially by stimulating the cortical circuitry more than, or at least differently from, non-voluntary passive motion. Yet, contrasting results are reported in the literature. We aimed here to investigate the importance of the integration of motor intention on cortical activity using functional near-infrared spectroscopy (fNIRS) by comparing the active use of an assistive exoskeleton targeting the shoulder with passive use and unassisted motion. We recorded the activity of the bilateral frontal and parietal cortices of 20 healthy individuals during an arm raising task. Active robot assistance showed similar activity patterns to unassisted motion with the exception of a greater activation of the prefrontal region. Correlates of intention could be confirmed by an activation of the supplementary motor area in active-assisted and unassisted but not passive condition. Activation of the contralateral primary sensorimotor regions did not differ between passive and active conditions but activity of the ipsilateral hemisphere and secondary regions was reduced during passive motion. Our results provide arguments in favor of the integration of the user's intention through physiological signals for rehabilitation, in favor of the investigation of secondary and ipsilateral regions, and in favor of the use of fNIRS to investigate differences in cortical correlates of passive and active motion.**

***Index Terms*— Cortical activity, functional near-infrared spectroscopy (fNIRS), robot-assisted rehabilitation, shoulder motion, voluntary intention.**

I. Introduction

IN THE past few years, the field of robot-assisted rehabilitation has seen exponential growth owing to technical improvements and the publication of promising results. It presents several advantages compared to typical rehabilitation approaches: it reduces the burden on therapists, offers high repeatability, repetition, and intensity, and it is thought to be more compelling for patients [1], [2], [3]. A subclass of the field is active assistance, which incorporates the intention of the patient, allowing voluntary training. If different control methods and ways to integrate the user's intention have been proposed (among which force sensors, position sensors,

Brain activity during upper-limb motion with the wearable cyborg HAL was visualized and quantified using functional near-infrared spectroscopy (fNIRS).

This study confirmed that, during motion assisted by HAL, higher-order motor areas in the brain were significantly activated in synchrony with the wearer's voluntary motor intention.

These findings demonstrate that HAL activates cortical regions associated with voluntary movement and suggest its potential to induce neuroplasticity in the brain. This provides scientific evidence supporting HAL®'s therapeutic mechanism, which promotes functional improvement and regeneration of the nervous and muscular systems.

Note: One of the authors of this study, Professor Kenji Suzuki of the University of Tsukuba, serves as an outside director of the Company and has certain economic interests in the Company.

Wearable Cyborg: Launch of rental sales for the next-generation Medical HAL Lower Limb Type (ML08)

Launch of rental sales for the new model of the Medical HAL Lower Limb Type (from May 2026)



Key Features of the New Model

✓Improved operational efficiency through size integration

Available in two types with different waist widths.
A single unit supports users from 150cm to 190cm in height, significantly simplifying operations compared to the conventional multi-size lineup.

✓More powerful and stable assistance

With a structure designed to firmly support the wearer and improved efficiency in transmitting assistive force, the system **enhances walking stability and provides greater confidence during use**.

✓Enabling more natural and comfortable walking

Enhanced algorithms with AI-based posture assessment enable more natural walking, making treadmill walking and faster-paced walking easier to perform. In addition, the design minimizes the sensation of device weight, reducing fatigue and improving comfort during extended use.

✓High durability and ease of use

Frame rigidity and durability have been improved, reducing wear and risk of failure. The design also minimizes loosening and misalignment during use, improving day-to-day operability.

Wearable Cyborg: Launch of the Slim HAL Lumbar Type (LB06).

Utilization across a wide range of worksites involving heavy physical labor, including emergency rescue operations, airports, factories, construction, logistics, and agriculture.

Key Features of the New Model

✓Achieving an ultra-slim design — lightweight and easy to wear

Its slim profile allows users to continue wearing it even during work in confined spaces or while operating vehicles.

Compared with the previous model, **the back thickness has been reduced by 65%**, resulting in a slim design that fits comfortably under outerwear.

The device can be put on in approximately 10 seconds for quick and easy use.

✓Supports squatting work with a wide stance

Naturally assists movements that place heavy strain on the lower back, such as lifting, twisting, and maintaining a half-sitting posture.

Combines the power and smooth motion unique to an active assistive device.

✓Visualization of physical workload and work conditions through IoH/IoT

Visualizes workers' physical workload and operational conditions.

Contributes to data-driven safety management and health-oriented workplace initiatives, including work risk analysis.

*Paid service

✓Integration with the compact vital sensor "Cyvis"

At worksites, the system is also expected to be utilized for worker health monitoring and heatstroke prevention measures.

【Prevention/Early detection, Diagnosis check】Small vital sensor “Cyvis”

Early detection, early treatment, and prognostic management of cardiovascular diseases — contributing to the prevention of stroke and dementia.

Through continuous daily monitoring, atrial fibrillation — which can lead to thrombus formation causing cerebral infarction and vascular dementia — can be detected and addressed at an early stage.

Key Features of Cyvis M100

✓ **Long-term continuous monitoring**
- Enables approximately 10 days of ECG monitoring on a single charge

✓ **Simultaneous measurement of various types of data**
- Acceleration (body movement) and angle
- Atmospheric pressure
- Body surface temperature, in-clothing temperature, and humidity*

*To be released in phases

✓ **Easy data review via app**
- Measurement data can be easily checked using a smartphone app
- Activity records can also be easily entered through the app

✓ **No manual data extraction required / Remote access available**
- Measurement data is automatically stored in a secure cloud via smartphone or tablet
- Data can also be viewed remotely through a PC browser

【Prevention/Early detection, Diagnosis check】Small vital sensor “Cyvis”

**By aggregating data in the cloud and utilizing AI analysis,
medical and non-medical fields can be interconnected and integrated.**

Hospital





Deployment as a medical device covered by insurance reimbursement (Holter ECG monitoring)

Emergency

Workplaces

Deployment as a corporate employee health management service

C-Cloud

Data sharing and centralized management

ECG data

Vital signs information

Analysis results and alerts

Home



Deployment as a personal healthcare (remote monitoring) service

Remote family members

Care facilities

Deployment as a resident monitoring service for care facilities and other organizations

Contrast-free, non-invasive, real-time, high-resolution 3D imaging

LED array method (patent held by CYBERDYNE)

Adopted as the cover of BioPhotonics, a U.S. industry journal dealing with biophotonics



Peripheral vascular and blood conditions, etc.

Peripheral level examination, which could not be done with conventional imaging equipment, is now possible!

Example of application

- **Routine examination and diagnosis of diabetic foot lesions**
- Examination of vascular regeneration status by regenerative medicine
- Examination and diagnosis of cancer
- Examination of aging skin, etc.

Currently promoting medical device commercialization as a next-generation medical diagnostic imaging device

Examples of business development for the “HCPS-Integrated Cybernics with Physical AI Platform”:As a medical technology solutions business that combines multiple Cybernics technologies, we plan to develop and expand next-generation treatment and care systems.

Wearable Cyborg “HAL”

Wearable Cyborg “HAL” including AI

driven by BioElectrical Signals derived from Brain

Vital Sensor “Cyvis”

Vital Sensor “Cyvis”

Bioelectrical Signal (ECG, EEG etc), Movement, BodyTemperature, SpO2 and Breath condition(option), etc



PhotoAcoustic Imaging System “AcousticX”

PhotoAcoustic Imaging System “AcousticX”

No Xray, No Contrast-media, Non-invasive, Real-time, High-resolution 3D imaging of Peripheral Blood Vessels



Clinical Research model

Medical device

An integrated approach encompassing prevention, early detection, treatment, and daily health management (monitoring and improvement).

Data acquired from each device is aggregated, AI-analyzed, and AI-processed through the C-Cloud platform, enabling the development of comprehensive medical and healthcare service businesses.

Examples of the HCPS-Integrated Cybernics with Physical AI Platform

Business development centered on Cybernics (HCPS-integrated Cybernics with Physical AI) within a fusion space of humans and cyber/physical space

Expanding our business operations and promote business development and R&D in the second stage

1st stage (Conventional products)

Promoting R&D, clinical research, clinical trials, insurance coverage, and global expansion centered on medical HAL for Cybernics treatment.
Deployment of AI-powered cleaning robots and AI image-processing 3D photoacoustic imaging systems.

2nd stage (Next-generation and new products)

Next-generation HAL

Slim HAL Lumbar Type

Next-generation Medical HAL Lower Limb Type

Cyvis + AI automated assessment

Compact vital sensor Cyvis M100

Cell culture Physical AI



Cell culture Physical AI

Autonomous and remote-operation Physical AI

Simplified hybrid autonomous/remote-operation Physical AI (to be progressively implemented in cleaning, transport, and AI mobility applications)

Advanced hybrid autonomous/remote-operation Physical AI (multi-purpose applications including biotechnology, maintenance, and operational tasks)

Photoacoustic + AI image processing: Medical AcousticX

Peripheral vascular and circulatory photoacoustic imaging AcousticX (medical device)

HCPS platform: C-Cloud (data aggregation and AI processing)

2026 2027

HCPS fusion technology：Cybernics/Human cooperative robotics

As a commitment to science, technology and innovation, CYBERDYNE participated in the Cabinet Office Strategic Innovation Creation Program (SIP) to strengthen growth strategies



1) Application to various living spaces such as houses, facilities, workplaces, etc.
2) Utilization of HCPS fusion master/remote control technology (Cybernic master/remote technology) integrated with human information (physiology, body, behavioral cognition, psychology, etc.)
3) Non-invasive acquisition and utilization of human information through HCPS fusion human collaborative robotics
4) Linking with other related technologies to improve the independence and freedom of seniors and people with mobility problems

Source: Cabinet Strategic Innovation Program (SIP), Secretariat of Science, Technology and Innovation, Cabinet Office, Government of Japan, “Development of Fundamental Technologies and Rules for Expanding Human-Coordinated Robotics: Strategy and R&D Plan for Social Implementation,” Pg 5.

Cybernics Master Remote Robot

Driving the Social Implementation of Physical AI through HCPS Integration

次世代ロボ、派遣業務担う

サイバーダイン、パソナと開発へ

装着型ロボット開発のCYBERDYNE（サイバーダイン）はパソナグループと組んで、人材派遣に活用できる次世代型ロボット開発に乗り出す。ひとの動きを遠隔操作でリアルタイムで忠実に再現する新型リモートロボを活用。一人で複数のロボを操作して省力化できる点を生かし、複数のロボに同時に複数の場所で作業させるなどして人手不足の解消や人材派遣コスト削減につなげる。

2月中旬、東京・南青山のパソナグループ本社で開いたサイバーダインの大阪・関西万博パソナ館への出展発表会で、同社の山海嘉之社長は「パソナはロボットを派遣する企業になりうる」と発言。サイボーグ型ロボットを人材派遣に活用する構想を明

ム」は、オペレ
遠隔操作で動く
グループ本社）

1人で複数操作

人手不足解消・コスト削減

ム」は、ひとの腕や指に装着したセンサーの動きをインターネット回線や高速大容量通信回線「5G」などでロボットに伝達。遠隔地にいるロボットをひとの動きに合わせて忠実に動かせる。

ロボットには4本があり、人間と同様の関節を持ち、ものをかんだり、手放したりできる。「4本指でも（山海社長）といい、料のボトルの蓋を開けるなど、微妙な力加減が要な動きもこなす。

レーターは、ロボット装着したカメラを通し見える空間を「拡張現（AR）ゴーグル」をして把握しながら操る。

サイバーダインが開した自律走行しながら港などの施設を自動で除するロボットの仕組

Feb 27, 2025 Nikkei

Clinical Development

Medical device approval for Medical HAL Lower Limb Type

Obtained medical device approvals and certifications in Europe and the US for cerebral palsy and spinal cord disorders

As of March 31, 2026

		Stroke	Spinal Cord Injury	Neuromuscular Disease*	Other diseases	Small size
Japan		(Preparing for additional trial)	(Communicating with regulators)	Approved	• HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
USA		Approved	Approved	Approved	• Cerebral palsy *Over 12 yrs old • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
EMEA	Europe	Approved	Approved	Approved	• Cerebral palsy • HTLV-1 Associated Myelopathy (HAM) • Hereditary spastic paraplegia	Approved
	Türkiye	Approved	Approved	Approved		
	Saudi Arabia	Approved	Approved	Approved		
APAC	Malaysia	Approved	Approved	Approved		
	Indonesia	Approved	Approved	Approved		
	Thailand	Approved	Approved	Approved		
	Singapore	Approved	Approved	Approved		
	India	Approved	Approved	Approved		
	Taiwan	Approved	Approved	(application in progress)		
	Australia	Approved	Approved	Approved		

*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy

Clinical Development Pipeline

As of March 31, 2026



Social implementation of Cybernics Treatment in Germany

Clinical trials to be conducted on the premise of German public medical insurance coverage

G-BA (German Federal Joint Committee) decides to conduct clinical trials under the premise of insurance coverage

G-BA approves Cybernics Treatment as the standard of care to be considered for spinal cord injury patients (in accordance with §137eSGB V of the Study Regulations)

G-BA itself decides to conduct a clinical trial (the clinical trial will be covered by public health insurance for Cybernics Treatment in advance).

The results of the clinical trial are expected to be included in the German public medical insurance system.

G-BA Preparing Clinical Trials (Selection of clinical trial sites has been completed.)

2023/01 Protocol outline presented

2023/03 Expert hearing held

2023/09 Protocol guideline announced

2024/11 CRO selection completed

G-BA (Federal Joint Committee): Organization at the federal level that determines basic benefits, prices, standards, etc. for German insurance treatment.
§137e SGB V (Trial Regulation): A system under which the G-BA conducts its own initiated clinical trials and makes final evaluations of promising treatments that could become the standard of care.

Global Expansion of Cybernics and Strengthening of International Collaboration

Strategy to promote Cybernics as a global platform

Strengthening cooperation with politics/government/academia/related industries around the world

Cyberdyne Care Robotics
(Germany)

CYBERDYNE HQ

EMEA Base
Cyberdyne Care Robotics GmbH (Germany)

Cooperselios
(Italy)

PERKESO – REHABILITATION CENTRE MELALA
(Malaysia)

APAC Base
CYBERDYNE MALAYSIA SDN. BHD.

Singapore General Hospital
(Singapore)

RISE Healthcare Group
(USA California)

Brooks Rehabilitation
(US Florida)

Americas Base
CYBERDYNE USA INC.

EMEA : Europe, Middle East and Africa

Social implementation of Cybernics (Malaysia)

The National Center for Neuro-Robotics and Cybernics, the largest medical complex in Southeast Asia

PERKESO National Neuro-Robotic and Cybernics Rehab. Centre

- ✓ Construction underway in Ipoh, Perak, Northern part of Malaysia (Scheduled by the end of 2024)
- ✓ First phase project
  - ✓ 15.6 Hectare (Approx. 3.4 baseball stadiums)
  - ✓ Gross floor area is approximately 86,400 square meters
- ✓ Capable of accommodating 700 patients at any given time

Maximum number of units to be installed at a single facility (65 units)

Opening ceremony scheduled for June 2026

Strategic base for social implementation of Cybernics Industry, such as HAL, Cybernics Products and technologies of other companies that CYBERDYNE invests through C-Startup

https://www.perkeso.gov.my/images/kenyataan_media/2023/190203_-_LAWATAN_MENTERI_SUMBER_MANUSIA_KE_TAPAK_PUSAT_REHABILITASI_PERKESO_PERAK.pdf?TSPD_101_R0=08e2dacd5fab2000f93a5be67765406ad4c598e4e5aedac205dcd286f8c106bc77d7648842ded7a008048fa483143000fbc3f707cd511bf1367c7352c9e10251d84d1723291abc11ccb8adcffc6ab4640a6f84d8e56752b87e7c10ac4d5baf7b

Social implementation of Cybernics (Malaysia)

Provides Cybernics Treatment free for patients due to Public Social Compensation Insurance

SOCSO/PERKESO (Malaysia Public Social Security Organization)

SOCSO has four functions: disability pension, survivor's pension, medical coverage and occupational injury coverage, and is compulsory for Malaysian and foreign workers in Malaysia to join the program. It provides medical compensation, disability compensation, funeral benefits, child support and nursing care benefits for illness or injury that occurs while commuting to and from work.

Facilities with HAL (14 facilities)

★ SOCSO/PERKESO Rehabilitation Center

Socso urged to build three new rehabilitation centres in five years

Bernama
15/01/2024 16:00 MYT

January 2024: The Minister of Human Resources requested the nationwide expansion of SOCSO (PERKESO) rehabilitation centers (three more locations, including Ipho, within five years).

https://www.astroawani.com/berita-malaysia/socso-urged-build-three-new-rehabilitation-centres-five-years-454129

Social implementation of Cybernics (Malaysia)

Human resource development in Malaysia
for the social implementation of HCPS-integrated Cybernics technology.

Comprehensive Collaboration with Universiti Malaysia Perlis (UniMAP)

2025.2

Universiti Malaysia Perlis (UniMAP)

A Malaysian government-established technical university with strengths in engineering and technology education.

Global Expansion of Cybernics and Strengthening of International Collaboration (US)

Signed a strategic MoU with Carnegie Mellon University (CMU), a global leader in AI and robotics research.

2025.12





https://www.cmu.edu/

As a strategic partner within the Pittsburgh region's innovation and healthcare ecosystem, we will further strengthen collaboration with regional medical institutions such as the University of Pittsburgh and UPMC, as well as community organizations including the Jewish Healthcare Foundation.

Global Expansion of Cybernics and Strengthening of International Collaboration (EMEA)

CYBERNICX FUTURE 2026

2026.1 Istanbul, Türkiye

Following the success of the inaugural event in 2024, the conference will be held again. Focusing on cutting-edge fields such as Cybernics, AI, regenerative medicine, and neuroscience, the event will explore the future of medicine and healthcare shaped by the fusion of humans and technology.

Inaugural event 2024.10

CYBERNICX FUTURE 2026

Joint Promotion of Cybernics Medical and Healthcare Innovation with National Taiwan University

Signing of an International MoU
2025.6.18

Co-hosting of an International Symposium at NTU
2025.11.2

Opening remarks by President Wen-Chang Chen, NTU

Delegation from National Taiwan University Hospital (NTUH)
2026.3.5

Global Expansion of Cybernics and Strengthening of International Collaboration (APAC)

“Cybernics Medical and Healthcare Innovation” with Thailand’s Institute of Geriatric Medicine (IGM-DMS)

2026.1.8

Utilizing HAL Lumbar Type to realize Healthy Aging

Photo caption (from left): Front row, left: Mr. Tatsushi Nishioka, Deputy Chief of Mission, Embassy of Japan in Thailand, Front row, right: Dr. Nutthapong Wongwiwat, Director-General, Department of Medical Services
Back row, center left: Dr. Yoshiyuki Sankai, President and CEO, CYBERDYNE Inc., Back row, center right: Dr. Bootsakorn Loharjun, Director, Institute of Geriatric Medicine
Back row, just right of center: Dr. Akkarathan Jittanuyanon, Deputy Director-General, Department of Medical Services

Disclaimer

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.


CYBERDYNE